Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

BioInvent International AB: BioStock: BioInvent kicks off 2025 with positive clinical data

BioInvent International

With multiple data readouts expected from its four clinical programs, BioInvent has started 2025 on a high note. The year's first clinical data show encouraging initial efficacy in the triple-combination of BI-1206, rituximab, and Calquence for treating non-Hodgkin's lymphoma. The company has also reported promising findings for BI-1910 as single agent in the phase I study targeting solid tumors. BioStock reached out to Martin Welschof, CEO of BioInvent for a comment.

Read the full interview with Martin Welschof at biostock.se:

https://www.biostock.se/en/2025/01/bioinvent-kicks-off-2025-with-positive-clinical-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.